Loomis Sayles & CO L P Inhibrx, Inc. Transaction History

Loomis Sayles & CO L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $496,755 - $1.3 Million	-34,259 Reduced 3.07%	1,082,225 $41.1 Million
Q3 2023 Nov 09, 2023	SELL	$15.75 - $26.31 $548,840 - $916,824	-34,847 Reduced 3.03%	1,116,484 $20.5 Million
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $180,640 - $296,310	-10,651 Reduced 0.92%	1,151,331 $29.9 Million
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $2.97 Million - $4.37 Million	161,176 Added 16.1%	1,161,982 $21.9 Million
Q4 2022 Feb 10, 2023	SELL	$20.18 - $33.33 $483,068 - $797,853	-23,938 Reduced 2.34%	1,000,806 $24.7 Million

Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $133,760 - $285,656	-11,551 Reduced 1.11%	1,024,744 $18.4 Million
Q2 2022 Aug 05, 2022	SELL	$8.52 - $25.26 $35,102 - $104,071	-4,120 Reduced 0.4%	1,036,295 $11.8 Million
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $20.7 Million - $44.9 Million	1,040,415 New	1,040,415 $23.2 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.